Biomea Fusion Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
1.69
0.1
(6.29%)
Volume:
868,399
52 week range:
1.53 - 13.43
Market Cap:
63.497M
Company Description:
Biomea Fusion, Inc. focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.